NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board
CALABASAS, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous...
What are the financing terms of the acquisition, including any dilution, debt issuance, or earn‑out provisions, and how might they impact shareholder returns in the short and medium term?
What is the expected contribution of Dr. Ishwar K. Puri’s expertise to the company's pipeline and how might it differentiate NeOnc from its CNS oncology peers?
How will the acquisition of AI, 3D bioprinting, and quantum modeling IP affect NeOnc's R&D timeline, cash burn, and overall valuation?
5 days ago